Neuronetics (STIM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
9 Apr, 2026Voting matters and shareholder proposals
Election of seven directors is up for vote, with all nominees recommended by the board.
Ratification of KPMG LLP as the independent registered public accounting firm is proposed.
Advisory approval of executive compensation is included as a non-binding vote.
Approval of the 2026 Equity Incentive Plan is on the agenda.
Other business may be addressed if properly brought before the meeting.
Board of directors and corporate governance
Seven director nominees are listed for election at the annual meeting.
Executive compensation and say-on-pay
Shareholders are asked to approve, on an advisory basis, the compensation of named executive officers.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Neuronetics
- Q2 2026 revenue up 9.1% to $41.6M, gross margin 51.1%, net loss narrowed, liquidity risks persist.STIM
Q2 2026 - Director elections, auditor ratification, and equity plan all approved without shareholder questions.STIM
AGM 2026 - Q1 revenue up 8% to $34.5M, net loss narrows, but going concern risk remains.STIM
Q1 2026 - Annual meeting to vote on directors, auditor, executive pay, and new equity plan, with strong governance focus.STIM
Proxy filing - Over 20 million shares registered for resale post-acquisition, with no proceeds to the company.STIM
Registration Filing - Q4 revenue up 86% YoY, 23% pro forma, with positive cash flow and 2026 growth outlook.STIM
Q4 2025 - Q3 revenue up 4% to $18.5M; Greenbrook deal approved, boosting growth and synergies.STIM
Q3 2024 - Acquisition and integration of Greenbrook TMS set the stage for growth and operational synergies.STIM
Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 - Record growth in new patient starts and adolescent market expansion set stage for 2025 breakeven.STIM
The 44th Annual William Blair Growth Stock Conference